Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Trial of Oxaloacetate in Alzheimer's Disease (TOAD)

Authors not listed

Russell Swerdlow · 2015

Abstract

The purpose of this study is to determine if oxaloacetate (OAA) is safe and tolerable at doses of up to 2 grams per day in people with Alzheimer's disease (AD).

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-01 MST

Cite this

APA
Anonymous. (2015). Trial of Oxaloacetate in Alzheimer's Disease (TOAD). <em>Russell Swerdlow</em>. https://clinicaltrials.gov/study/NCT02593318
Vancouver
Anonymous. Trial of Oxaloacetate in Alzheimer's Disease (TOAD). Russell Swerdlow. 2015.
BibTeX
@misc{anon2015Trialo, title = {Trial of Oxaloacetate in Alzheimer's Disease (TOAD)}, author = {Anonymous}, journal = {Russell Swerdlow}, year = {2015}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings